Close Window

Digital Look Email A Friend

GSK to buy Boston-based biopharma firm Nuvalent for $10.6bn

Published by Michele Maatouk on 9th June 2026

(Sharecast News) - GSK said on Tuesday that it has agreed to buy Boston-based oncology-focused biopharmaceutical firm Nuvalent for $10.6bn (£7.9bn).

URL: http://www.digitallook.com/dl/news/story/35987073/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.